Brii Bio Unveils Promising Phase 2 Trial Results for HBV Treatment Strategies#USA#Denver#Brii_Bio#BRII-179#HBV_Treatment
Brii Bio Unveils Promising Phase 2 Trial Results for HBV Treatment Strategies
Brii Bio recently shared groundbreaking data from its Phase 2 studies on BRII-179, showcasing its role in enhancing HBV treatments at AASLD 2026.
third-news.com
November 6, 2026 at 12:21 AM
Brii Bio Unveils Promising Phase 2 Trial Results for HBV Treatment Strategies#USA#Denver#Brii_Bio#BRII-179#HBV_Treatment
Brii Bio Reports Promising Phase 2b Study Results for Chronic Hepatitis B Treatment#USA#Durham#Hepatitis_B#Brii_Bio#BRII-179
Brii Bio Reports Promising Phase 2b Study Results for Chronic Hepatitis B Treatment
Brii Bio announces positive end-of-treatment outcomes from its Phase 2b studies on BRII-179, highlighting its potential in treating chronic Hepatitis B.
third-news.com
July 3, 2026 at 12:11 AM
Brii Bio Reports Promising Phase 2b Study Results for Chronic Hepatitis B Treatment#USA#Durham#Hepatitis_B#Brii_Bio#BRII-179
Brii Bio's ENSURE Study Unveils Promising HBsAg Clearance Data At EASL Congress 2025#USA#Durham#Brii_Bio#BRII-179#ENSURE_Study
Brii Bio's ENSURE Study Unveils Promising HBsAg Clearance Data At EASL Congress 2025
Exciting new data from Brii Bio's ongoing ENSURE study highlights BRII-179's effectiveness in enhancing HBsAg seroclearance rates in HBV patients, offering hope for better treatment outcomes.
third-news.com
May 8, 2025 at 12:13 AM
Brii Bio's ENSURE Study Unveils Promising HBsAg Clearance Data At EASL Congress 2025#USA#Durham#Brii_Bio#BRII-179#ENSURE_Study
Brii Bio Strengthens Position with Acquisition of BRII-179 IP Rights and Completes Patient Enrollment for ENRICH Study#China#Beijing#Brii_Bio#BRII-179#HBV_Therapy
Brii Bio Strengthens Position with Acquisition of BRII-179 IP Rights and Completes Patient Enrollment for ENRICH Study
Brii Biosciences Limited enhances its future with the acquisition of BRII-179 intellectual property rights and successful enrollment in the ENRICH study, aiming at improved HBV therapies.
third-news.com
December 31, 2024 at 11:20 AM
Brii Bio Strengthens Position with Acquisition of BRII-179 IP Rights and Completes Patient Enrollment for ENRICH Study#China#Beijing#Brii_Bio#BRII-179#HBV_Therapy